Adrenergic beta-agonist
Adrenergic beta-agonists (beta-agonists) are "drugs that selectively bind to and activate beta-adrenergic receptors."[1]
Medical uses
Asthma
- See Asthma
Among patients with asthma, LABAs, tend to increase serious adverse effects and mortality. This harm is reduced, but not definitely eliminated, when LABAs are combined with corticosteroids.[2]
Chronic obstructive pulmonary disease
Among patients with COPD, reduction in mortality may not occur unless LABAs are combined with corticosteroids.[3]
Drug toxicity
Long acting adrenergic beta-agonists (LABA) associated with may adverse outcomes among patients with asthma when used without corticosteroids and maybe among African American patients.[4] They might be safe in asthma as long as corticosteroids are used. According to a meta-analyses by the Cochrane Collaboration, when used with corticosteroids the relative risk for asthma-related death is increased at 1.34 although this increase was not statistically significant with a confidence interval of 0.30 to 5.97.[5][2] There are two major randomized controlled trials of LABAs. The SNS study compared salmeterol to salbutamol[6] while the SMART study compared salmeterol to placebo.[7]
References
- ↑ Anonymous (2024), Adrenergic beta-agonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Cates CJ, Cates MJ (2008). "Regular treatment with salmeterol for chronic asthma: serious adverse events". Cochrane Database Syst Rev (3): CD006363. DOI:10.1002/14651858.CD006363.pub2. PMID 18646149. Research Blogging.
- ↑ Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R (May 2008). "Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review". Chest 133 (5): 1079–87. DOI:10.1378/chest.07-1167. PMID 18460518. Research Blogging.
- ↑ Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE (2006). "Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths". Ann. Intern. Med. 144 (12): 904-12. PMID 16754916. [e]
- ↑ Walters EH, Gibson PG, Lasserson TJ, Walters JA (2007). "Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid". Cochrane Database Syst Rev (1): CD001385. DOI:10.1002/14651858.CD001385.pub2. PMID 17253458. Research Blogging.
- ↑ Castle W, Fuller R, Hall J, Palmer J (April 1993). "Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment". BMJ 306 (6884): 1034–7. PMID 8098238. PMC 1676982. [e]
- ↑ Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (January 2006). "The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol". Chest 129 (1): 15–26. DOI:10.1378/chest.129.1.15. PMID 16424409. Research Blogging.